Connect your AI

Beam Therapeutics BEAM Restricted Cash

Restricted Cash at other companies

CRISPR TherapeuticsCRSP

$7.63M-4.7%

Cogent Biosciences, Inc.COGT

$416K—

Protagonist TherapeuticsPTGX

$288K+28.0%

IncyteINCY

$1.84M+10.3%

Vertex PharmaceuticalsVRTX

——

BridgeBio PharmaBBIO

——

Other financials

Income statement

Revenue$31.7M+325%

Operating income-$107.2M+10.1%

Net income-$94.3M+12.9%

EPS (diluted)-$0.91+26.0%

Balance sheet

Cash & equivalents$288.3M-45.4%

Total debt$250.8M+58.6%

Total equity$1.2B+3.1%

Total assets$1.5B+0.9%

Cash flow

Operating cash flow-$128.5M-23.7%

CapEx$2.2M-27.2%

Free cash flow-$130.7M-22.2%

Valuation

Market cap$3.42B+24.5%

Profitability

Operating margin-226.6%-90.5pp

Net margin-742.7%—

FCF margin-234%-86.6pp

Returns & leverage

Return on equity-47.1%—

Debt / equity0.2×+0.1×

Current ratio17×+8.2×

Where this comes from

Reported directly by Beam Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.

The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Beam Therapeutics's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Beam Therapeutics's restricted cash?: Beam Therapeutics (BEAM) reported restricted cash of $6.69M in Q1 2026.
How has Beam Therapeutics's restricted cash changed year-over-year?: Beam Therapeutics's restricted cash increased by 1.3% year-over-year, from $6.61M to $6.69M.
What is the long-term trend for Beam Therapeutics's restricted cash?: Over 5 years (2020 to 2025), Beam Therapeutics's restricted cash has grown at a -14.8% compound annual growth rate (CAGR), from $14.84M to $6.68M.
What does restricted cash mean?: Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.